Continuing Lamotrigine Through Breastfeeding in the Postpartum Window
A single patient, three weeks postpartum and six years stable on lamotrigine. Continuing it through breastfeeding carries a real, monitorable infant exposure risk — stopping it carries the highest relapse risk of her entire illness course.
A.D. is a 34-year-old marketing manager who conceived via IVF after three years of trying, and gave birth three weeks ago to a healthy daughter. She has bipolar I disorder and has been maintained on lamotrigine 300mg daily for six years, including throughout this pregnancy, with no mood episodes and no complications. She is exclusively breastfeeding and describes it, unprompted, as one of the parts of motherhood she fought hardest to get to after years of fertility treatment — she is not neutral about whether it continues, and she has already told the team plainly that she would want a very strong reason before giving it up.
Lamotrigine crosses into breast milk at a meaningfully higher relative infant dose than most psychiatric medications, and it carries its own boxed warning for rare but serious rash, including Stevens-Johnson syndrome, a risk that in principle extends to an exposed infant as well as to the patient taking it directly. Against that sits the fact that she is currently three weeks into the postpartum period, the single highest-risk window for relapse across the entire course of bipolar illness, and lamotrigine is the drug that has kept her stable for six straight years without interruption — through a job change, the stress of infertility treatment, and now a pregnancy, without a single breakthrough episode. Stopping it, or switching to something with a more reassuring lactation profile but no proven track record for her specifically, both carry their own real cost, and neither is obviously the more conservative choice once her actual history is taken into account rather than just the drug label in isolation.
Weighing infant exposure against postpartum relapse risk
The rash risk in a breastfed infant from maternal lamotrigine is rare, but it is not theoretical — cases have been reported, and a newborn can't tell anyone that something feels wrong. I want a concrete monitoring plan in place, not just a general reassurance that the data are mostly favorable.
Concretely: any rash, unusual lethargy, or poor feeding in the baby should prompt an immediate call, not a wait-and-see approach until the next scheduled visit.
I want to weigh the relapse side of this with equal seriousness. Lamotrigine is the only drug that has kept her stable for six years, and she is currently in the highest-risk window of her entire illness course for a recurrence. Switching agents now, during the postpartum period specifically, trades a monitorable infant risk for an unproven regimen at the worst possible time to be testing one.
The relative infant dose data for lamotrigine, while higher than many psychiatric drugs, still falls within a range most lactation resources consider compatible with breastfeeding with monitoring — this isn't a case where the data are silent or alarming, it's a case where "compatible with monitoring" has to actually mean monitoring, not just a phrase in a reference book.
Lamotrigine continued unchanged at 300mg daily. Breastfeeding continued, with explicit instructions to call immediately for any infant rash, unusual lethargy, or poor feeding rather than waiting for a scheduled visit, and a two-week pediatric follow-up added specifically to check on the infant outside the routine newborn visit schedule.
The team was clear with her that this plan carries a real, if small, monitored risk to the infant rather than a risk-free path — she was an active participant in that discussion, not simply informed of a decision made for her, and she was explicit that continuing to breastfeed mattered enough to her to accept the monitoring plan rather than switch agents.